Research programme: coronavirus vaccines - Antigen Express/Generex

Drug Profile

Research programme: coronavirus vaccines - Antigen Express/Generex

Alternative Names: SARS vaccine - Antigen Express/Generex; Severe Acute Respiratory Syndrome vaccine - Antigen Express/Generex

Latest Information Update: 03 Feb 2012

Price : $50

At a glance

  • Originator Antigen Express; Generex Biotechnology Corporation
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Coronavirus infections

Most Recent Events

  • 03 Feb 2012 No development reported - Preclinical for Coronavirus infections in Canada (unspecified route)
  • 03 Feb 2012 No development reported - Preclinical for Coronavirus infections in USA (unspecified route)
  • 15 Aug 2003 Antigen Express has been acquired by Generex Biotechnology Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top